Ginkgo Bioworks
Ginkgo Bioworks raises $1.5B PIPE at $15B valuation
Quick Facts
Ginkgo Bioworks: PIPE Funding Round
Ginkgo Bioworks has successfully raised $1.5B in PIPE funding, reaching a valuation of $15B.
Company Overview
Synthetic biology and organism engineering platform
Funding Details
The PIPE round was led by Cathay Innovation, with participation from Baillie Gifford, Counterpoint Global, General Atlantic, Sumitomo Chemical, Viking Global, Cascade Investment.
Company Information
- Headquarters: 27 Drydock Avenue, Boston, MA 02210
- Founded: 2008
- Employees: 700+
- Category: Biotech
Investment
Ginkgo Bioworks plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cathay Innovation: Verified investor in PIPE
- Baillie Gifford: Verified investor in PIPE
- Counterpoint Global: Verified investor in PIPE
- General Atlantic: Verified investor in PIPE
- Sumitomo Chemical: Verified investor in PIPE
- Viking Global: Verified investor in PIPE
- Cascade Investment: Verified investor in PIPE
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...